Drugs / Avandamet
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Avandamet | — | 2013-10-20 | europa.eu ↗ |
| Approved | EU (EMA) | Avandamet | — | 2003-10-20 | europa.eu ↗ |
| Approved | US (FDA) | AVANDAMET | — | 2002-10-10 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00131664 Comparator | Sep 2005 → Jan 2008 | type 2 diabetes mellitus | Canadian Heart Research Centre | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avandamet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00131664 ↗ |
| Route | Oral | “AvandametTM combines two oral antihyperglycemic agents” NCT00131664 ↗ |